Adamax

Adamax is a laboratory-synthesized peptide built on the ACTH(4–10) fragment scaffold — the same core sequence as Semax — extended with Ala-Gly at the C-terminus and modified with an adamantyl moiety at the terminal residue. N-terminal acetylation and C-terminal amidation complete the structural design. The adamantyl group is a rigid lipophilic cage incorporated in other neurotrophic peptide analogs to study how hydrophobic additions affect CNS penetration and metabolic stability. Published studies cited in subsequent sections were conducted on Semax or structurally related ACTH-analog peptides; Adamax has not been independently characterized in published peer-reviewed research, and citations describe research attributed to the molecules actually examined. Research on this structural class applies radioligand binding assays, brain membrane preparations, and intranasal rodent administration methods to characterize binding site engagement, distribution in neural tissue, and proteolytic resistance relative to non-modified parent sequences.

A central focus of ACTH(4–10)-derived peptide research is the neurotrophic factor axis. Studies in rat brain models measure BDNF and NGF mRNA and protein levels — particularly in hippocampal and basal forebrain regions — using qPCR, ELISA, and immunohistochemistry. Dolotov et al. (2006) applied radioligand techniques and BDNF measurement in rat basal forebrain to examine binding site characteristics and neurotrophin levels following intranasal peptide administration. Markov et al. (2023) surveyed how melanocortin peptide analogs of this class engage neurotrophic signaling pathways, providing a comparative framework for how structural modifications correlate with receptor and neurotrophin endpoints. TrkB receptor engagement, CREB phosphorylation, and downstream signaling cascade readouts are standard molecular endpoints in this research context.

Research on ACTH-fragment analogs in neural injury contexts employs rodent focal ischemia models as the primary experimental platform. Medvedeva et al. (2014) performed genome-wide transcriptional profiling in a rat permanent focal ischemia (pMCAO) model, examining how peptide treatment correlates with expression of immune-response, vascular, and neurotransmitter-related gene sets. Sudarkina et al. (2021) extended this approach to transient MCAO (tMCAO), applying protein-level analysis to examine signaling markers — including CREB, MMP-9, c-Fos, and JNK — in ischemic brain tissue. These studies characterize which molecular pathways and proteomic changes are assessed in neural injury models and illustrate the experimental framework through which ACTH-analog peptides of this structural class are evaluated.

ACTH-fragment analogs appear in Alzheimer's-related research using both transgenic mouse models and in vitro aggregation assays. Radchenko et al. (2025) employed APP/PS1 transgenic mice — a standard amyloid pathology model — to examine ACTH-analog peptides over an extended timeline, using behavioral tasks (open field, novel object recognition, Barnes maze) alongside histological analysis of amyloid plaques. In a complementary in vitro line of work, Sciacca et al. (2022) used artificial membrane preparations and cell culture to examine how an ACTH-analog peptide interacts with amyloid-β in the presence of copper ions, monitoring fibril formation dynamics. Both contexts illustrate the assay frameworks — behavioral batteries, transgenic histology, and biophysical membrane models — through which peptides of this structural class are evaluated in Alzheimer's research.

At the molecular level, the research methods applied to ACTH(4–10)-derived peptides include radioligand competition binding in brain membrane preparations, whole-genome transcriptome arrays in neural tissue, RT-qPCR quantification of neurotrophin mRNAs, ELISA-based protein quantification, and electrophysiological recordings in cultured neurons. Gene expression profiling — in cultured glial cells, primary neurons, and whole-brain extracts — characterizes the transcriptional context of peptide administration in preclinical models. Behavioral assays (maze tasks, avoidance paradigms, open-field and stress tests) run in parallel with neurochemical endpoints measuring monoamine neurotransmitter profiles and cytokine levels via HPLC and immunoassay.